These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 16729912)

  • 1. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ; Sarao H
    Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
    Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
    Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
    Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
    Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ; Hernandez-McClain J; Henary H
    Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
    Kelly WK; Zhu AX; Scher H; Curley T; Fallon M; Slovin S; Schwartz L; Larson S; Tong W; Hartley-Asp B; Pellizzoni C; Rocchetti M
    Clin Cancer Res; 2003 Jun; 9(6):2098-107. PubMed ID: 12796374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.